Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient
- 252 Downloads
In a prior randomized phase II trial comparing hyperthermic isolated limb perfusion (HILP) with four different doses of tumor necrosis factor alpha (TNF-α), no dose effect was detected for response, but systemic toxicity was far lower with low-dose TNF-α. The objective of the present study was to confirm these data on a larger sample size of locally advanced or recurrent extremity soft tissue sarcomas with low-dose TNF-α.
We assessed a prospective database comprising 100 HILP (38–40°C) with melphalan (10 mg/L) and TNF-α (1 mg). The remnant tumor was resected 2 months later.
Among 52 recurrences, 18 were in a previously irradiated field. Stages according to the American Joint Committee on Cancer classification were II (19 patients), III (78 patients), and IV (3 patients). The site/size were: 30 patients/57 mm and 70 patients/86 mm for the upper and lower limbs, respectively. Tumor grades (FNCLCC) were 1 (23 patients), 2 (34 patients), and 3 (43 patients). Fifty-one patients had received systemic chemotherapy before HILP. Responses on magnetic resonance imaging were 30% complete, 49% partial, 9% no change, and 12% progression. No mortality or systemic toxicity occurred. Local toxicity (Wieberdink) attained grade 2 (16 patients), 3 (5 patients), and 4 (1 patient). Limbs were able to be saved in 87% patients. Three-year overall survival and the local recurrence rate were 89% and 18%, respectively. Age, sex, tumor size, recurrence, uni- or multifocality, grade, preoperative chemotherapy, and a previously irradiated field were not predictive of response or local toxicity.
We confirm that 1 mg of TNF-α is as effective as the standard dose and results in no systemic toxicity.
KeywordsLocal Recurrence Rate Limb Salvage Spin Echo Isolate Limb Perfusion Local Toxicity
We thank Lorna Saint Ange for editing.
- 2.Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg. 1992;215:269–7.Google Scholar
- 11.Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224:756–64.CrossRefPubMedGoogle Scholar
- 20.Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Insitute of Canada. J Natl Cancer Inst. 2000;92:205–6.CrossRefPubMedGoogle Scholar
- 21.Baumert BG, Spahr MO, Von Hochstetter A, et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol. 2007;2:12.Google Scholar
- 24.Tumor of bone and soft tissues. R classification. In Sobin LH, Wittekind Ch, eds. TNM Classification of Malignant Tumours, UICC. 6th ed. New York: Wiley Liss, 2002:110.Google Scholar
- 25.World Health Organization (WHO). WHO Handbook for Reporting Results of Cancer Treatment. Publication 48. Geneva: WHO, 1979.Google Scholar
- 40.Olieman AF, Pras E, van Ginkel RJ, et al. Feasibility and efficacy ofexternal beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys. 1998;40:807–14.CrossRefPubMedGoogle Scholar
- 50.Bonvalot S, Muret J, Debaere T, et al. High response rates with isolated pelvic perfusion (IPP) with a pneumatic anti-shock garments (PASG) and low-dose TNF-α for locally advanced pelvic sarcomas and carcinomas: a phase II unicenter trial (abstract 10586). J Clin Oncol. 2008;26(Suppl).Google Scholar